GenSci128

· Changchun GeneScience Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GenSci128, covering 2025-12-30 to 2025-12-30. Get the full timeline:

Most recent: Clinical Trial Update: A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation [Phase 1]

See pricing